Skip to main content
Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Mavacamten for treating obstructive hypertrophic cardiomyopathy
Drug guidance

Mavacamten for treating obstructive hypertrophic cardiomyopathy

Condition

Cardiovascular

4 June 2025

Guidance Recommendations

Funding status

Back to top